Chart looking good Maxter
EOFY might see some more selling ( hopefully some bargain buying for some).
2 half of 2017 is promising, with 1b ovarian and closely followed by 1b AML trail results.
It's possible that PTX will have 3 phase two studies and one phase 1a study coming in to 2018.
Reciting the words of our CEO, exciting times ahead.
